Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
11.41
-0.33 (-2.81%)
At close: Feb 20, 2026, 4:00 PM EST
11.19
-0.22 (-1.93%)
After-hours: Feb 20, 2026, 5:38 PM EST
Xencor Employees
Xencor had 250 employees as of December 31, 2024. The number of employees decreased by 30 or -10.71% compared to the previous year.
Employees
250
Change (1Y)
-30
Growth (1Y)
-10.71%
Revenue / Employee
$600,528
Profits / Employee
-$523,292
Market Cap
814.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 250 | -30 | -10.71% | 250 | 0 |
| Dec 31, 2023 | 280 | -1 | -0.36% | 280 | 0 |
| Dec 31, 2022 | 281 | 27 | 10.63% | 281 | 0 |
| Dec 31, 2021 | 254 | 52 | 25.74% | 254 | 0 |
| Dec 31, 2020 | 202 | 36 | 21.69% | 202 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 430 |
| KalVista Pharmaceuticals | 270 |
| Omeros | 202 |
| Janux Therapeutics | 109 |
| Fulcrum Therapeutics | 45 |
| Arbutus Biopharma | 44 |
| Bright Minds Biosciences | 26 |
XNCR News
- 6 weeks ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 7 weeks ago - Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 - Seeking Alpha
- 2 months ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 3 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire
- 4 months ago - Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript - Seeking Alpha
- 4 months ago - Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Business Wire
- 4 months ago - Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Business Wire